A_clinical_and_experimental_study_on_all-trans_retinoic_acid-treated_acute_promyelocytic_leukemia_patients._Fifty_patients_with_acute_promyelocytic_leukemia_(APL)_have_been_treated_with_all-trans_retinoic_acid_(RA)._In_vitro_induced_differentiation_of_primarily_cultured_bone_marrow_cells_from_the_patients,_colony-forming_unit_granulocyte-macrophage_(CFU-GM)_and_L-CFU_colony-forming_assays,_and_karyotype_analysis_were_performed_over_the_treatment_course._The_very_high_bone_marrow_complete_remission_(CR)_rate_(94%)_suggested_that_all-trans_RA_was_superior_to_conventional_chemotherapeutic_regimens_for_the_treatment_of_APL._The_leukemic_clone_was_reduced_by_RA-induced_terminal_differentiation_and_loss_of_proliferation_capacity_of_leukemic_cells._Relapse_after_CR_in_about_40%_of_patients_was_the_major_reason_for_the_failure_of_the_RA_treatment._Patients_who_relapsed_after_a_chemotherapy-maintained_CR_could_be_effectively_reinduced_to_second_CR_by_RA._However,_if_relapse_occurred_after_a_CR_maintained_by_both_RA_and_chemotherapy,_the_sensitivity_of_newly_emerged_leukemic_clones_to_RA_was_greatly_reduced._Therefore,_it_is_suggested_that_RA_should_be_replaced_by_conventional_chemotherapy_as_soon_as_CR_is_achieved._Laboratory_studies_proved_valuable_in_selecting_cases_for_RA_therapy_and_in_predicting_therapeutic_effects_and_prognosis.